Company news
BioMarin Pharmaceutical Inc. news in 2020
BioMarin Pharmaceutical Inc.'s news releases, calls and decks from 2020, newest first.
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
December 20, 2020
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
November 16, 2020
BioMarin Expands Vosoritide Clinical Program
November 8, 2020
BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
November 4, 2020
BioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 12: 30pm ET
November 3, 2020
Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia
November 1, 2020
BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4: 30pm ET
October 21, 2020
BioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU
October 6, 2020
Scientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early Development
October 4, 2020
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
October 1, 2020
BioMarin to Participate in Upcoming Virtual Investor Conference
September 28, 2020
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy
September 23, 2020
BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting
September 10, 2020
BioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data Demonstrating Statistically Significant Increase in Annualized Growth Velocity (AGV) Over 52 Weeks in Children with Achondroplasia
September 7, 2020
BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia
August 19, 2020
BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
August 18, 2020
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia
August 12, 2020
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
August 3, 2020
BioMarin Submits Marketing Authorization Application to European Medicines Agency for Vosoritide to Treat Children with Achondroplasia
July 22, 2020
BioMarin to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 4 at 4: 30pm ET
July 20, 2020
BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO
June 28, 2020
BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference
June 22, 2020
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
June 16, 2020
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
May 30, 2020
BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027
May 18, 2020
BioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinated Convertible Notes
May 10, 2020
BioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering
May 10, 2020
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
May 2, 2020
BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
April 28, 2020
BioMarin Updates Timing of First Quarter 2020 Financial Results Conference Call and Webcast to Wednesday, April 29 at 4: 15pm ET
April 21, 2020
BioMarin Appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations, Effective May 4
April 20, 2020
BioMarin to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, April 30 at 4: 30pm ET
April 13, 2020
BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe
April 5, 2020
BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
February 25, 2020
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
February 19, 2020
BioMarin Announces CFO Succession
February 2, 2020
BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4: 30pm ET
January 28, 2020
BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy
January 12, 2020
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
January 1, 2020